News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly (LLY)'s Solanezumab And The History Of The Future Of Treating Alzheimer's Disease



11/11/2016 7:44:46 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Today, in America, a high school freshman studying science is as old as the last Food and Drug Administration (FDA) approved treatment for Alzheimer’s disease. Soon, this may change.

By the close of this year, the Indianapolis based Fortune 500 pharmaceutical company Lilly, whose products have included the anti-depressant Prozac and human insulin, will release the results of Expedition 3, a study testing a drug that targets amyloid in persons with mild stage dementia caused by Alzheimer’s disease. Its subjects are unique. They don’t simply have Alzheimer’s disease diagnosed by a careful history and exam. They have a brain scan showing amyloid accumulation.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES